Icatibant - treatment of acute attacks of hereditary angioedema;Icatibant Behandlung akuter Schwellungsanfälle des hereditären Angioödems (HAE)

Arzneimitteltherapie

Volumn 27, Issue 4, 2009, Pages 109-113

  Magerl, Markus ^a,b   Keßler, Birgit ^a,b   Maurer, Marcus ^a,b   Musch, Annemarie ^a,c  

^a Allergie Centrum Charité ^*

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NONE   (Germany)

Author keywords

bradykinin; C1 esterase inhibitor; HAE; Hereditary angioedema; Icatibant

Indexed keywords

FIRAZYR; ICATIBANT; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; HUMAN; REVIEW;

EID: 77950508522     PISSN: 07236913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. Zuraw BL. Hereditary Angioedema. N Engl J Med 2008;359:1027-36.
2. Bork K, G4uUl D, Hardt J, Dewald G. Hereditary angioedema with normal CI inhibitor: clinical symptoms and course. Am J Med 2007;120:987-92.
3. Nussberger J, Cugno M, Amstutz C, Cicardi M, et. al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-7.
4. Fachinformation Firazyr®; Stand Juli 2008.
5. http://www.emea.europa.eu/humandocs/PDFs/EPAR/firazyr/H-899-en6. pdf